Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 235 entries
Sorted by: Best Match Show Resources per page
Revealing Nature's Cellulase Diversity: The Digestion Mechanism of Caldicellulosiruptor bescii CelA

diversity

Brunecky R, Alahuhta M, Xu Q, Donohoe BS.
GSID: IieGVQ6oYn8J
R Brunecky, M Alahuhta, Q Xu, BS Donohoe… - Science, 2013 - science.org

Most fungi and bacteria degrade plant cell walls by secreting free, complementary enzymes that hydrolyze cellulose; however, some bacteria use large enzymatic assemblies called cellulosomes, which recruit complementary enzymes to protein scaffolds. The thermophilic …

Cite
Brunecky, R., Alahuhta, M., Xu, Q., Donohoe, B. S., Crowley, M. F., Kataeva, I. A., ... & Bomble, Y. J. (2013). Revealing nature’s cellulase diversity: the digestion mechanism of Caldicellulosiruptor bescii CelA. Science, 342(6165), 1513-1516.
Brunecky, Roman, et al. "Revealing nature’s cellulase diversity: the digestion mechanism of Caldicellulosiruptor bescii CelA." Science 342.6165 (2013): 1513-1516.
Copy Download .nbib Format: MLA
Biomass accessibility analysis using electron tomography.

Biotechnology for biofuels

Hinkle JD, Ciesielski PN, Gruchalla K, Munch KR, Donohoe BS.
PMID: 26709354
Biotechnol Biofuels. 2015 Dec 25;8:212. doi: 10.1186/s13068-015-0395-8. eCollection 2015.

BACKGROUND: Substrate accessibility to catalysts has been a dominant theme in theories of biomass deconstruction. However, current methods of quantifying accessibility do not elucidate mechanisms for increased accessibility due to changes in microstructure following pretreatment.RESULTS: We introduce methods for...

Cite
Hinkle JD, Ciesielski PN, Gruchalla K, et al. Biomass accessibility analysis using electron tomography. Biotechnol Biofuels. 2015;8:212doi: 10.1186/s13068-015-0395-8.
Hinkle, J. D., Ciesielski, P. N., Gruchalla, K., Munch, K. R., & Donohoe, B. S. (2015). Biomass accessibility analysis using electron tomography. Biotechnology for biofuels, 8212. https://doi.org/10.1186/s13068-015-0395-8
Hinkle, Jacob D, et al. "Biomass accessibility analysis using electron tomography." Biotechnology for biofuels vol. 8 (2015): 212. doi: https://doi.org/10.1186/s13068-015-0395-8
Hinkle JD, Ciesielski PN, Gruchalla K, Munch KR, Donohoe BS. Biomass accessibility analysis using electron tomography. Biotechnol Biofuels. 2015 Dec 25;8:212. doi: 10.1186/s13068-015-0395-8. eCollection 2015. PMID: 26709354; PMCID: PMC4691013.
Copy Download .nbib Format: NLM
Thymectomy for myasthenia gravis: what's next?.

Journal of thoracic disease

de Perrot M, Donahoe L.
PMID: 28275468
J Thorac Dis. 2017 Feb;9(2):237-239. doi: 10.21037/jtd.2017.02.32.

No abstract available.

Cite
de Perrot M, Donahoe L. Thymectomy for myasthenia gravis: what's next?. J Thorac Dis. 2017;9(2):237-239doi: 10.21037/jtd.2017.02.32.
de Perrot, M., & Donahoe, L. (2017). Thymectomy for myasthenia gravis: what's next?. Journal of thoracic disease, 9(2), 237-239. https://doi.org/10.21037/jtd.2017.02.32
de Perrot, Marc, and Donahoe, Laura. "Thymectomy for myasthenia gravis: what's next?." Journal of thoracic disease vol. 9,2 (2017): 237-239. doi: https://doi.org/10.21037/jtd.2017.02.32
de Perrot M, Donahoe L. Thymectomy for myasthenia gravis: what's next?. J Thorac Dis. 2017 Feb;9(2):237-239. doi: 10.21037/jtd.2017.02.32. PMID: 28275468; PMCID: PMC5334076.
Copy Download .nbib Format: NLM
WA42 Proving its worth - changing public policy for palliative care, end of life care and bereavement through advocacy and communications.

BMJ supportive & palliative care

Edghill A, Donohoe M.
PMID: 25960464
BMJ Support Palliat Care. 2015 Apr;5:A13. doi: 10.1136/bmjspcare-2015-000906.42.

BACKGROUND: The 2015 palliative care budget is €72 million (Euros) but up to €1.3 billion spent on end of life care annually - much of this larger figure unplanned and uncoordinated. Geographic and other inequities evident in palliative care...

Cite
Edghill A, Donohoe M. WA42 Proving its worth - changing public policy for palliative care, end of life care and bereavement through advocacy and communications. BMJ Support Palliat Care. 2015;5:A13doi: 10.1136/bmjspcare-2015-000906.42.
Edghill, A., & Donohoe, M. (2015). WA42 Proving its worth - changing public policy for palliative care, end of life care and bereavement through advocacy and communications. BMJ supportive & palliative care, 5A13. https://doi.org/10.1136/bmjspcare-2015-000906.42
Edghill, Angela, and Donohoe, Miriam. "WA42 Proving its worth - changing public policy for palliative care, end of life care and bereavement through advocacy and communications." BMJ supportive & palliative care vol. 5 (2015): A13. doi: https://doi.org/10.1136/bmjspcare-2015-000906.42
Edghill A, Donohoe M. WA42 Proving its worth - changing public policy for palliative care, end of life care and bereavement through advocacy and communications. BMJ Support Palliat Care. 2015 Apr;5:A13. doi: 10.1136/bmjspcare-2015-000906.42. PMID: 25960464.
Copy Download .nbib Format: NLM
Luxury primary care.

The New England journal of medicine

Donohoe M.
PMID: 12195593
N Engl J Med. 2002 Aug 22;347(8):618-20; author reply 618-20.

No abstract available.

Cite
Donohoe M. Luxury primary care. N Engl J Med. 2002;347(8):618-20; author reply 618-20
Donohoe, M. (2002). Luxury primary care. The New England journal of medicine, 347(8), 618-20; author reply 618-20.
Donohoe, Martin. "Luxury primary care." The New England journal of medicine vol. 347,8 (2002): 618-20; author reply 618-20.
Donohoe M. Luxury primary care. N Engl J Med. 2002 Aug 22;347(8):618-20; author reply 618-20. PMID: 12195593.
Copy Download .nbib Format: NLM
1-Phenyl-1,2-dicarba-closo-dodecaborane, 1-Ph-1,2-closo-C(2)B(10)H(11). Synthesis, Characterization, and Structure As Determined in the Gas Phase by Electron Diffraction, in the Crystalline Phase at 199 K by X-ray Diffraction, and by ab Initio Computations.

Inorganic chemistry

Brain PT, Cowie J, Donohoe DJ, Hnyk D, Rankin DW, Reed D, Reid BD, Robertson HE, Welch AJ, Hofmann M, Schleyer PR.
PMID: 11666394
Inorg Chem. 1996 Mar 13;35(6):1701-1708. doi: 10.1021/ic9511128.

The compound 1-phenyl-1,2-dicarba-closo-dodecaborane(12), 1-C(6)H(5)-1,2-closo-C(2)B(10)H(11) (1), has been synthesized and characterized by a complete assignment of its (11)B NMR spectrum via (11)B{(1)H}/(11)B{(1)H} (COSY), (1)H{(11)B(selective)} and (1)H{(11)B}/(1)H{(11)B} (COSY) spectroscopy. An electron- and X-ray diffraction investigation of 1, complemented by ab initio...

Cite
Brain PT, Cowie J, Donohoe DJ, et al. 1-Phenyl-1,2-dicarba-closo-dodecaborane, 1-Ph-1,2-closo-C(2)B(10)H(11). Synthesis, Characterization, and Structure As Determined in the Gas Phase by Electron Diffraction, in the Crystalline Phase at 199 K by X-ray Diffraction, and by ab Initio Computations. Inorg Chem. 1996;35(6):1701-1708doi: 10.1021/ic9511128.
Brain, P. T., Cowie, J., Donohoe, D. J., Hnyk, D., Rankin, D. W., Reed, D., Reid, B. D., Robertson, H. E., Welch, A. J., Hofmann, M., & Schleyer, P. R. (1996). 1-Phenyl-1,2-dicarba-closo-dodecaborane, 1-Ph-1,2-closo-C(2)B(10)H(11). Synthesis, Characterization, and Structure As Determined in the Gas Phase by Electron Diffraction, in the Crystalline Phase at 199 K by X-ray Diffraction, and by ab Initio Computations. Inorganic chemistry, 35(6), 1701-1708. https://doi.org/10.1021/ic9511128
Brain, Paul T., et al. "1-Phenyl-1,2-dicarba-closo-dodecaborane, 1-Ph-1,2-closo-C(2)B(10)H(11). Synthesis, Characterization, and Structure As Determined in the Gas Phase by Electron Diffraction, in the Crystalline Phase at 199 K by X-ray Diffraction, and by ab Initio Computations." Inorganic chemistry vol. 35,6 (1996): 1701-1708. doi: https://doi.org/10.1021/ic9511128
Brain PT, Cowie J, Donohoe DJ, Hnyk D, Rankin DW, Reed D, Reid BD, Robertson HE, Welch AJ, Hofmann M, Schleyer PR. 1-Phenyl-1,2-dicarba-closo-dodecaborane, 1-Ph-1,2-closo-C(2)B(10)H(11). Synthesis, Characterization, and Structure As Determined in the Gas Phase by Electron Diffraction, in the Crystalline Phase at 199 K by X-ray Diffraction, and by ab Initio Computations. Inorg Chem. 1996 Mar 13;35(6):1701-1708. doi: 10.1021/ic9511128. PMID: 11666394.
Copy Download .nbib Format: NLM
Evidence-based medicine and shaken baby syndrome: part I: literature review, 1966-1998.

The American journal of forensic medicine and pathology

Donohoe M.
PMID: 12960659
Am J Forensic Med Pathol. 2003 Sep;24(3):239-42. doi: 10.1097/01.paf.0000083635.85457.97.

No abstract available.

Cite
Donohoe M. Evidence-based medicine and shaken baby syndrome: part I: literature review, 1966-1998. Am J Forensic Med Pathol. 2003;24(3):239-42doi: 10.1097/01.paf.0000083635.85457.97.
Donohoe, M. (2003). Evidence-based medicine and shaken baby syndrome: part I: literature review, 1966-1998. The American journal of forensic medicine and pathology, 24(3), 239-42. https://doi.org/10.1097/01.paf.0000083635.85457.97
Donohoe, Mark. "Evidence-based medicine and shaken baby syndrome: part I: literature review, 1966-1998." The American journal of forensic medicine and pathology vol. 24,3 (2003): 239-42. doi: https://doi.org/10.1097/01.paf.0000083635.85457.97
Donohoe M. Evidence-based medicine and shaken baby syndrome: part I: literature review, 1966-1998. Am J Forensic Med Pathol. 2003 Sep;24(3):239-42. doi: 10.1097/01.paf.0000083635.85457.97. PMID: 12960659.
Copy Download .nbib Format: NLM
Edward L. Thorndike: the selectionist connectionist.

Journal of the experimental analysis of behavior

Donahoe J.
PMID: 16812924
J Exp Anal Behav. 1999 Nov;72(3):451-4. doi: 10.1901/jeab.1999.72-451.

No abstract available.

Cite
Donahoe J. Edward L. Thorndike: the selectionist connectionist. J Exp Anal Behav. 1999;72(3):451-4doi: 10.1901/jeab.1999.72-451.
Donahoe, J. (1999). Edward L. Thorndike: the selectionist connectionist. Journal of the experimental analysis of behavior, 72(3), 451-4. https://doi.org/10.1901/jeab.1999.72-451
Donahoe, J. "Edward L. Thorndike: the selectionist connectionist." Journal of the experimental analysis of behavior vol. 72,3 (1999): 451-4. doi: https://doi.org/10.1901/jeab.1999.72-451
Donahoe J. Edward L. Thorndike: the selectionist connectionist. J Exp Anal Behav. 1999 Nov;72(3):451-4. doi: 10.1901/jeab.1999.72-451. PMID: 16812924; PMCID: PMC1284756.
Copy Download .nbib Format: NLM
Cancer cachexia: mechanisms and clinical implications.

Gastroenterology research and practice

Donohoe CL, Ryan AM, Reynolds JV.
PMID: 21760776
Gastroenterol Res Pract. 2011;2011:601434. doi: 10.1155/2011/601434. Epub 2011 Jun 13.

Cachexia is a multifactorial process of skeletal muscle and adipose tissue atrophy resulting in progressive weight loss. It is associated with poor quality of life, poor physical function, and poor prognosis in cancer patients. It involves multiple pathways: procachectic...

Cite
Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:601434doi: 10.1155/2011/601434.
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011). Cancer cachexia: mechanisms and clinical implications. Gastroenterology research and practice, 2011601434. https://doi.org/10.1155/2011/601434
Donohoe, Claire L, et al. "Cancer cachexia: mechanisms and clinical implications." Gastroenterology research and practice vol. 2011 (2011): 601434. doi: https://doi.org/10.1155/2011/601434
Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:601434. doi: 10.1155/2011/601434. Epub 2011 Jun 13. PMID: 21760776; PMCID: PMC3132494.
Copy Download .nbib Format: NLM
Women in applied behavior analysis.

The Behavior analyst

McSweeney FK, Donahoe P, Swindell S.
PMID: 22478351
Behav Anal. 2000;23(2):267-77. doi: 10.1007/BF03392015.

The status of women in applied behavior analysis was examined by comparing the participation of women in the Journal of Applied Behavior Analysis (JABA) to their participation in three similar journals. For all journals, the percentage of articles with...

Cite
McSweeney FK, Donahoe P, Swindell S. Women in applied behavior analysis. Behav Anal. 2000;23(2):267-77doi: 10.1007/BF03392015.
McSweeney, F. K., Donahoe, P., & Swindell, S. (2000). Women in applied behavior analysis. The Behavior analyst, 23(2), 267-77. https://doi.org/10.1007/BF03392015
McSweeney, F K, et al. "Women in applied behavior analysis." The Behavior analyst vol. 23,2 (2000): 267-77. doi: https://doi.org/10.1007/BF03392015
McSweeney FK, Donahoe P, Swindell S. Women in applied behavior analysis. Behav Anal. 2000;23(2):267-77. doi: 10.1007/BF03392015. PMID: 22478351; PMCID: PMC2731339.
Copy Download .nbib Format: NLM
Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth.

International journal of oncology

Boveri J, Parry R, Ruffin W, Gustafson M, Lee K, He W, Donahoe P.
PMID: 21573527
Int J Oncol. 1993 Feb;2(2):135-43.

Mullerian Inhibiting Substance (MIS), a gonadal growth factor important in sexual differentiation, has antiproliferative activity against several human carcinoma cell lines. In this study, we examine the effect of MIS-transfection on the growth characteristics of Chinese hamster ovary (CHO)...

Cite
Boveri J, Parry R, Ruffin W, et al. Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth. Int J Oncol. 1993;2(2):135-43
Boveri, J., Parry, R., Ruffin, W., Gustafson, M., Lee, K., He, W., & Donahoe, P. (1993). Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth. International journal of oncology, 2(2), 135-43.
Boveri, J, et al. "Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth." International journal of oncology vol. 2,2 (1993): 135-43.
Boveri J, Parry R, Ruffin W, Gustafson M, Lee K, He W, Donahoe P. Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth. Int J Oncol. 1993 Feb;2(2):135-43. PMID: 21573527.
Copy Download .nbib Format: NLM
4-Bromo-2-(5-bromo-thio-phen-2-yl)-1-[(5-bromo-thio-phen-2-yl)meth-yl]-5,6-dimethyl-1H-benzimidazole.

Acta crystallographica. Section E, Structure reports online

Geiger HC, Donohoe JS, Geiger DK.
PMID: 24826179
Acta Crystallogr Sect E Struct Rep Online. 2014 Mar 26;70:o486-7. doi: 10.1107/S160053681400628X. eCollection 2014 Apr 01.

The title compound, C18H13Br3N2S2, was obtained via the reaction of N-bromo-succinamide with 5,6-dimethyl-2-(thio-phen-2-yl)-1-[(thio-phen-2-yl)meth-yl]-1H-benzimidazole. The compound exhibits rotational disorder of the 5-bromo-thio-phen-2-yl substituent with a refined major:minor occupancy ratio of 0.876 (7):0.124 (7). The 5-bromo-thio-phen-2-yl mean plane is canted to...

Cite
Geiger HC, Donohoe JS, Geiger DK. 4-Bromo-2-(5-bromo-thio-phen-2-yl)-1-[(5-bromo-thio-phen-2-yl)meth-yl]-5,6-dimethyl-1H-benzimidazole. Acta Crystallogr Sect E Struct Rep Online. 2014;70:o486-7doi: 10.1107/S160053681400628X.
Geiger, H. C., Donohoe, J. S., & Geiger, D. K. (2014). 4-Bromo-2-(5-bromo-thio-phen-2-yl)-1-[(5-bromo-thio-phen-2-yl)meth-yl]-5,6-dimethyl-1H-benzimidazole. Acta crystallographica. Section E, Structure reports online, 70o486-7. https://doi.org/10.1107/S160053681400628X
Geiger, H Cristina, et al. "4-Bromo-2-(5-bromo-thio-phen-2-yl)-1-[(5-bromo-thio-phen-2-yl)meth-yl]-5,6-dimethyl-1H-benzimidazole." Acta crystallographica. Section E, Structure reports online vol. 70 (2014): o486-7. doi: https://doi.org/10.1107/S160053681400628X
Geiger HC, Donohoe JS, Geiger DK. 4-Bromo-2-(5-bromo-thio-phen-2-yl)-1-[(5-bromo-thio-phen-2-yl)meth-yl]-5,6-dimethyl-1H-benzimidazole. Acta Crystallogr Sect E Struct Rep Online. 2014 Mar 26;70:o486-7. doi: 10.1107/S160053681400628X. eCollection 2014 Apr 01. PMID: 24826179; PMCID: PMC3998606.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 235 entries